VisCardia, Inc. was founded with the mission to innovate in the field of heart failure treatment through advanced medical devices. The company's core vision is to improve the quality of life for patients suffering from chronic heart conditions. VisCardia offers a novel implantable device therapy known as Synchronized Diaphragmatic Stimulation (SDS® therapy), which aims to enhance ventricular function by synchronizing diaphragmatic activity. The primary market focus for VisCardia is the United States, where it serves patients and healthcare providers looking for cutting-edge solutions to manage heart failure.

Notable individuals affiliated with VisCardia include experienced professionals in medical device development and cardiovascular research. The company has garnered attention from key investors in the medical technology sector, supporting its innovative approach. Among its key achievements, VisCardia has demonstrated sustained improvements in cardiac function through clinical trials and animal studies, showcasing the efficacy of its SDS® therapy. The overall impact of VisCardia's work is significant, offering a promising new avenue for treating chronic heart failure and potentially transforming patient outcomes in this challenging medical field.